Tyrosine kinase inhibitor-induced hypothyroidism: mechanism and clinical implications

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) are effective anti-cancer agents improving patient survival.
• TKIs target various tyrosine kinases, inhibiting cancer cell signaling pathways.
• Adverse reactions, particularly thyroid dysfunction, are emerging concerns with TKI therapy.

Purpose of the Study:

• To review the epidemiology of hypothyroidism in cancer patients treated with TKIs.
• To elucidate the potential mechanisms underlying TKI-induced thyroid dysfunction.
• To discuss the clinical significance and implications of this adverse effect.

Main Methods:

• Literature review of studies on TKI therapy and thyroid function.
• Analysis of epidemiological data on hypothyroidism incidence.
• Synthesis of proposed mechanisms for TKI-induced thyroid dysfunction.

Main Results:

• Hypothyroidism is a common adverse event in patients receiving TKI therapy.
• The precise mechanisms linking TKIs to thyroid dysfunction remain largely unclear.
• Thyroid dysfunction is associated with TKI treatment efficacy.

Conclusions:

• Hypothyroidism is a clinically relevant complication of TKI cancer treatment.
• Further research is needed to fully understand and manage TKI-induced thyroid dysfunction.
• Monitoring thyroid function is crucial for patients undergoing TKI therapy.